{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:01:59Z","timestamp":1780524119121,"version":"3.54.1"},"reference-count":59,"publisher":"IMR Press","issue":"12","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Royal Perth Hospital- Research Foundation WA","award":["VM2018"],"award-info":[{"award-number":["VM2018"]}]},{"name":"Diabetes Australia Research Program","award":["Y20G-MATV"],"award-info":[{"award-number":["Y20G-MATV"]}]},{"name":"Diabetes Research WA","award":["DRWA-LHerat-2020"],"award-info":[{"award-number":["DRWA-LHerat-2020"]}]},{"name":"Raine Medical Research Foundation, WA","award":["Raine-LHerat-2020"],"award-info":[{"award-number":["Raine-LHerat-2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: Diabetic retinopathy (DR) is a major cause of blindness globally. Sodium Glucose Cotransporter-2 (SGLT2) inhibitors have been demonstrated to exert cardiorenal protection in patients with diabetes. However, their potential beneficial effect on DR is less well studied. The aim of the present study was to determine the effects of the SGLT2 inhibition with Dapagliflozin (DAPA) on DR in well-characterised DR mouse models and controls. Methods: Dapagliflozin was administered to mice with and without diabetes for 8 weeks via their drinking water at 25 mg\/kg\/day. Urine glucose levels were measured weekly and their response to glucose was tested at week 7. After 8 weeks of treatment, eye tissue was harvested under terminal anaesthesia. The retinal vasculature and neural structure were assessed using immunofluorescence, immunohistochemistry and electron microscopy techniques. Results: Dapagliflozin treated DR mice exhibited metabolic benefits reflected by healthy body weight gain and pronounced glucose tolerance. Dapagliflozin reduced the development of retinal microvascular and neural abnormalities, increased the beneficial growth factor FGF21 (Fibroblast Growth Factor 21). We highlight for the first time that SGLT2 inhibition results in the upregulation of SGLT1 protein in the retina and that SGLT1 is significantly increased in the diabetic retina. Conclusions: Blockade of SGLT2 activity with DAPA may reduce retinal microvascular lesions in our novel DR mouse model. In conclusion, our data demonstrates the exciting future potential of SGLT1 and\/or SGLT2 inhibition as a therapeutic for DR.<\/jats:p>","DOI":"10.31083\/j.fbl2712321","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T09:06:17Z","timestamp":1671181577000},"source":"Crossref","is-referenced-by-count":15,"title":["Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy"],"prefix":"10.31083","volume":"27","author":[{"given":"Lakshini Y.","family":"Herat","sequence":"first","affiliation":[{"name":"Dobney Hypertension Centre, School of Biomedical Science \u2013 Royal Perth Hospital Unit, University of Western Australia, 6009 Crawley, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Matthews","sequence":"first","affiliation":[{"name":"Dobney Hypertension Centre, School of Biomedical Science \u2013 Royal Perth Hospital Unit, University of Western Australia, 6009 Crawley, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei E.","family":"Ong","sequence":"first","affiliation":[{"name":"Dobney Hypertension Centre, School of Biomedical Science \u2013 Royal Perth Hospital Unit, University of Western Australia, 6009 Crawley, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth P.","family":"Rakoczy","sequence":"first","affiliation":[{"name":"Department of Molecular Ophthalmology, University of Western Australia, 6009 Crawley, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus P.","family":"Schlaich","sequence":"first","affiliation":[{"name":"Dobney Hypertension Centre, School of Medicine \u2013 Royal Perth Hospital Unit, University of Western Australia, 6009 Crawley, WA, Australia"},{"name":"Department of Cardiology, Royal Perth Hospital, 6000 Perth, WA, Australia"},{"name":"Department of Nephrology, Royal Perth Hospital, 6000 Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vance B.","family":"Matthews","sequence":"first","affiliation":[{"name":"Dobney Hypertension Centre, School of Biomedical Science \u2013 Royal Perth Hospital Unit, University of Western Australia, 6009 Crawley, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice. 2018; 138: 271\u2013281.","DOI":"10.1016\/j.diabres.2018.02.023"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Congdon N, Zheng Y, He M. The worldwide epidemic of diabetic retinopathy. Indian Journal of Ophthalmology. 2012; 60: 428.","DOI":"10.4103\/0301-4738.100542"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Grading diabetic retinopathy from stereoscopic color fundus photographs\u2013an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98: 786\u2013806.","DOI":"10.1016\/S0161-6420(13)38012-9"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003; 110: 1677\u20131682.","DOI":"10.1016\/S0161-6420(03)00475-5"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. International Journal of Molecular Sciences. 2018; 19: 1816.","DOI":"10.3390\/ijms19061816"},{"key":"ref6","unstructured":"Crimi S, Cipolli D, Infantone E, Infantone L, Lunetta M. Microalbuminuria and severity of diabetic retinopathy in type 1 diabetic patients: association and relationship with some risk factors. Diabetes & Metabolism. 1995; 21: 440\u2013445."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Hirsch IB, Brownlee M. Beyond hemoglobin A1c\u2013need for additional markers of risk for diabetic microvascular complications. JAMA. 2010; 303: 2291\u20132292.","DOI":"10.1001\/jama.2010.785"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008; 115: 1859\u20131868.","DOI":"10.1016\/j.ophtha.2008.08.023"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Sano R, Shinozaki Y, Ohta T. Sodium\u2013glucose cotransporters: Functional properties and pharmaceutical potential. Journal of Diabetes Investigation. 2020; 11: 770\u2013782.","DOI":"10.1111\/jdi.13255"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Wright EM. The Intestinal Na+\/Glucose Cotransporter. Annual Review of Physiology. 1993; 55: 575\u2013589.","DOI":"10.1146\/annurev.physiol.55.1.575"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Chao EC, Henry RR. SGLT2 inhibition \u2014 a novel strategy for diabetes treatment. Nature Reviews Drug Discovery. 2010; 9: 551\u2013559.","DOI":"10.1038\/nrd3180"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Xiang B, Zhao X, Zhou X. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients. Cardiovascular Diabetology. 2021; 20: 78.","DOI":"10.1186\/s12933-021-01266-x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Dutka M, Bobi\u0144ski R, Ulman-W\u0142odarz I, Hajduga M, Bujok J, Paj\u0105k C, et al. Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure. Heart Failure Reviews. 2021; 26: 603\u2013622.","DOI":"10.1007\/s10741-020-10041-1"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Lehmann A, Hornby PJ. Intestinal SGLT1 in metabolic health and disease. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2016; 310: G887\u2013G898.","DOI":"10.1152\/ajpgi.00068.2016"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Song P, Onishi A, Koepsell H, Vallon V. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opinion on Therapeutic Targets. 2016; 20: 1109\u20131125.","DOI":"10.1517\/14728222.2016.1168808"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Matthews J, Herat L, Rooney J, Rakoczy E, Schlaich M, Matthews VB. Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy. Bioscience Reports. 2022; 42: BSR20212209.","DOI":"10.1042\/BSR20212209"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Lim JC, Perwick RD, Li B, Donaldson PJ. Comparison of the expression and spatial localization of glucose transporters in the rat, bovine and human lens. Experimental Eye Research. 2017; 161: 193\u2013204.","DOI":"10.1016\/j.exer.2017.06.012"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Herat LY, Matthews VB, Rakoczy PE, Carnagarin R, Schlaich M. Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy. International Journal of Endocrinology. 2018; 2018: 9254126.","DOI":"10.1155\/2018\/9254126"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"van Eeden PE, Tee LBG, Lukehurst S, Lai C, Rakoczy EP, Beazley LD, et al. Early Vascular and Neuronal Changes in a VEGF Transgenic Mouse Model of Retinal Neovascularization. Investigative Opthalmology & Visual Science. 2006; 47: 4638.","DOI":"10.1167\/iovs.06-0251"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Investigative Ophthalmology & Visual Science. 2005; 46: 2210-2218.","DOI":"10.1167\/iovs.04-1340"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Rakoczy EP, Rahman ISA, Binz N, Li C, Vagaja NN, de Pinho M, et al. Characterization of a Mouse Model of Hyperglycemia and Retinal Neovascularization. The American Journal of Pathology. 2010; 177: 2659\u20132670.","DOI":"10.2353\/ajpath.2010.090883"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Lai C. Generation of transgenic mice with mild and severe retinal neovascularisation. British Journal of Ophthalmology. 2005; 89: 911\u2013916.","DOI":"10.1136\/bjo.2004.059089"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Chaurasia SS, Lim RR, Parikh BH, Wey YS, Tun BB, Wong TY, et al. The NLRP3 Inflammasome may Contribute to Pathologic Neovascularization in the Advanced Stages of Diabetic Retinopathy. Scientific Reports. 2018; 8: 2847.","DOI":"10.1038\/s41598-018-21198-z"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"McLenachan S, Magno AL, Ramos D, Catita J, McMenamin PG, Chen FK, et al. Angiography reveals novel features of the retinal vasculature in healthy and diabetic mice. Experimental Eye Research. 2015; 138: 6\u201321.","DOI":"10.1016\/j.exer.2015.06.023"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wisniewska-Kruk J, Klaassen I, Vogels IMC, Magno AL, Lai C, Van Noorden CJF, et al. Molecular analysis of blood\u2013retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy. Experimental Eye Research. 2014; 122: 123\u2013131.","DOI":"10.1016\/j.exer.2014.03.005"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Vagaja NN, Chinnery HR, Binz N, Kezic JM, Rakoczy EP, McMenamin PG. Changes in Murine Hyalocytes are Valuable Early Indicators of Ocular Disease. Investigative Opthalmology & Visual Science. 2012; 53: 1445\u20131451.","DOI":"10.1167\/iovs.11-8601"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Weerasekera LY, Balmer LA, Ram R, Morahan G. Characterization of Retinal Vascular and Neural Damage in a Novel Model of Diabetic Retinopathy. Investigative Opthalmology & Visual Science. 2015; 56: 3721\u20133730.","DOI":"10.1167\/iovs.14-16289"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Barber AJ, Baccouche B. Neurodegeneration in diabetic retinopathy: Potential for novel therapies. Vision Research. 2017; 139: 82\u201392.","DOI":"10.1016\/j.visres.2017.06.014"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Barber AJ, Gardner TW, Abcouwer SF. The Significance of Vascular and Neural Apoptosis to the Pathology of Diabetic Retinopathy. Investigative Opthalmology & Visual Science. 2011; 52: 1156\u20131163.","DOI":"10.1167\/iovs.10-6293"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Mizutani M, Gerhardinger C, Lorenzi M. M\u00fcller cell changes in human diabetic retinopathy. Diabetes. 1998; 47: 445\u2013449.","DOI":"10.2337\/diabetes.47.3.445"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Feit-Leichman RA, Kinouchi R, Takeda M, Fan Z, Mohr S, Kern TS, et al. Vascular Damage in a Mouse Model of Diabetic Retinopathy: Relation to Neuronal and Glial Changes. Investigative Opthalmology & Visual Science. 2005; 46: 4281\u20134287.","DOI":"10.1167\/iovs.04-1361"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Rizzolo LJ. Glucose Transporters in Retinal Pigment Epithelium Development. In Tombran-Tink J, Barnstable CJ (ed) Ocular Transporters In Ophthalmic Diseases And Drug Delivery: Ophthalmology Research (pp. 185\u2013199). Humana Press: Totowa, NJ. 2008.","DOI":"10.1007\/978-1-59745-375-2_10"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Gong Q, Zhang R, Wei F, Fang J, Zhang J, Sun J, et al. SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db\/db mice. Biomedicine & Pharmacotherapy. 2022; 152: 113222.","DOI":"10.1016\/j.biopha.2022.113222"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Takakura S, Toyoshi T, Hayashizaki Y, Takasu T. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sciences. 2016; 147: 125\u2013131.","DOI":"10.1016\/j.lfs.2016.01.042"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Hu Y, Xu Q, Li H, Meng Z, Hao M, Ma X, et al. Dapagliflozin Reduces Apoptosis of Diabetic Retina and Human Retinal Microvascular Endothelial Cells Through ERK1\/2\/cPLA2\/AA\/ROS Pathway Independent of Hypoglycemic. Frontiers in Pharmacology. 2022; 13: 827896.","DOI":"10.3389\/fphar.2022.827896"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Breyer MD, B\u00f6ttinger E, Brosius FC, Coffman TM, Harris RC, Heilig CW, et al. Mouse Models of Diabetic Nephropathy. Journal of the American Society of Nephrology. 2005; 16: 27\u201345.","DOI":"10.1681\/ASN.2004080648"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Kim AK, Hamadani C, Zeidel ML, Hill WG. Urological complications of obesity and diabetes in males and females of three mouse models: temporal manifestations. American Journal of Physiology-Renal Physiology. 2020; 318: F160\u2013F174.","DOI":"10.1152\/ajprenal.00207.2019"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Matthews JR, Schlaich MP, Rakoczy EP, Matthews VB, Herat LY. The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy. Biomedicines. 2022; 10: 522.","DOI":"10.3390\/biomedicines10030522"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Herat LY, Ward NC, Magno AL, Rakoczy EP, Kiuchi MG, Schlaich MP, et al. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. World Journal of Gastroenterology. 2020; 26: 3225\u20133235.","DOI":"10.3748\/wjg.v26.i23.0000"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Miyata KN, Zhao S, Wu C, Lo C, Ghosh A, Chenier I, et al. Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice. Diabetes Research and Clinical Practice. 2020; 162: 108107.","DOI":"10.1016\/j.diabres.2020.108107"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Yaginuma H, Banno R, Sun R, Taki K, Mizoguchi A, Kobayashi T, et al. Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice. Journal of Pharmacological Sciences. 2021; 147: 340\u2013347.","DOI":"10.1016\/j.jphs.2021.08.010"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al. Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats. Diabetes. 2008; 57: 1723\u20131729.","DOI":"10.2337\/db07-1472"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes. JAMA Cardiology. 2021; 6: 148\u2013158.","DOI":"10.1001\/jamacardio.2020.4511"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Cho EH, Park S, Han S, Song JH, Lee K, Chung Y. Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy. Journal of Diabetes Research. 2018; 2018: 6807219.","DOI":"10.1155\/2018\/6807219"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Chung YR, Ha KH, Lee K, Kim DJ. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study. PLoS ONE. 2019; 14: e0224549.","DOI":"10.1371\/journal.pone.0224549"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Taher MM, Shoukry HS. Protective Effect of Sodium-Glucose Co-Transporter 2 Inhibitor (Dapagliflozin) on Diabetic Retinopathy in Streptozotocin Induced Diabetes in Rats. The Medical Journal of Cairo University. 2019; 87: 465\u2013470.","DOI":"10.21608\/mjcu.2019.52382"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Luo Q, Leley SP, Bello E, Dhami H, Mathew D, Bhatwadekar AD. Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes. BMJ Open Diabetes Research & Care. 2022; 10: e002801.","DOI":"10.1136\/bmjdrc-2022-002801"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Hanaguri J, Yokota H, Kushiyama A, Kushiyama S, Watanabe M, Yamagami S, et al. The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice. International Journal of Molecular Sciences. 2022; 23: 1362.","DOI":"10.3390\/ijms23031362"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Eid SA, O\u2019Brien PD, Hinder LM, Hayes JM, Mendelson FE, Zhang H, et al. Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes. Biology. 2020; 9: 347.","DOI":"10.3390\/biology9110347"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D. Circulating Fibroblast Growth Factor-21 is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates with Muscle and Hepatic Insulin Resistance. Diabetes Care. 2009; 32: 1542\u20131546.","DOI":"10.2337\/dc09-0684"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Chen C, Cheung BMY, Tso AWK, Wang Y, Law LSC, Ong KL, et al. High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care. 2011; 34: 2113\u20132115.","DOI":"10.2337\/dc11-0294"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Fu Z, Gong Y, Liegl R, Wang Z, Liu C, Meng SS, et al. FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice. Cell Reports. 2017; 18: 1606\u20131613.","DOI":"10.1016\/j.celrep.2017.01.014"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Fu Z, Wang Z, Liu C, Gong Y, Cakir B, Liegl R, et al. Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice. Diabetes. 2018; 67: 974\u2013985.","DOI":"10.2337\/db17-0830"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Tomita Y, Fu Z, Wang Z, Cakir B, Cho SS, Britton W, et al. Long-Acting FGF21 Inhibits Retinal Vascular Leakage in In Vivo and In Vitro Models. International Journal of Molecular Sciences. 2020; 21: 1188.","DOI":"10.3390\/ijms21041188"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Tomita Y, Ozawa N, Miwa Y, Ishida A, Ohta M, Tsubota K, et al. Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model. International Journal of Molecular Sciences. 2019 Nov 23;20(23):5878.","DOI":"10.3390\/ijms20235878"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Tomita Y, Lee D, Miwa Y, Jiang X, Ohta M, Tsubota K, Kurihara T. Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy. International Journal of Molecular Sciences. 2020; 21: 6243.","DOI":"10.3390\/ijms21176243"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Rosell Rask S, Krarup Hansen T, Bjerre M. FGF21 and glycemic control in patients with T1D. Endocrine. 2019; 65: 550\u2013557.","DOI":"10.1007\/s12020-019-02027-3"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Martinez-Martin FJ, Jimenez-Martin N, Sablon-Gonzalez N. SGLT1 does compensate for SGLT2 inhibition. European Heart Journal - Cardiovascular Pharmacotherapy. 2016; 2: 256\u2013256.","DOI":"10.1093\/ehjcvp\/pvw014"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. American Journal of Physiology-Renal Physiology. 2014; 306: F188\u2013F193.","DOI":"10.1152\/ajprenal.00518.2013"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/12\/10.31083\/j.fbl2712321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:25:51Z","timestamp":1732710351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/12\/10.31083\/j.fbl2712321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2768-6701(22)00697-9"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2712321","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"article-number":"321"}}